Optimal Modalities for HCC Surveillance in a High-Incidence Region

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2021 Jan 25

PMID 33489094

Authors

Young Chang

Jeong-Hoon Lee

Affiliations

Soon will be listed here.

Citing Articles

Application of artificial intelligence in the diagnosis of hepatocellular carcinoma.

Koh B, Danpanichkul P, Wang M, Tan D, Ng C eGastroenterology. 2025; 1(2):e100002.

PMID: 39944000 PMC: 11770452. DOI: 10.1136/egastro-2023-100002.

References

Kanwal F, Singal A . Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology. 2019; 157(1):54-64. PMC: 6636644. DOI: 10.1053/j.gastro.2019.02.049. View

van Meer S, de Man R, Coenraad M, Sprengers D, van Nieuwkerk K, Klumpen H . Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands. J Hepatol. 2015; 63(5):1156-63. DOI: 10.1016/j.jhep.2015.06.012. View

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

Singal A, Nehra M, Adams-Huet B, Yopp A, Tiro J, Marrero J . Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?. Am J Gastroenterol. 2013; 108(3):425-32. PMC: 5560895. DOI: 10.1038/ajg.2012.449. View

Singal A, Volk M, Waljee A, Salgia R, Higgins P, Rogers M . Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009; 30(1):37-47. PMC: 6871653. DOI: 10.1111/j.1365-2036.2009.04014.x. View

Simmons O, Fetzer D, Yokoo T, Marrero J, Yopp A, Kono Y . Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2016; 45(1):169-177. PMC: 7207219. DOI: 10.1111/apt.13841. View

Pocha C, Dieperink E, McMaken K, Knott A, Thuras P, Ho S . Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. Aliment Pharmacol Ther. 2013; 38(3):303-12. DOI: 10.1111/apt.12370. View

Omata M, Cheng A, Kokudo N, Kudo M, Lee J, Jia J . Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11(4):317-370. PMC: 5491694. DOI: 10.1007/s12072-017-9799-9. View

Kim H, Nam J, Lee J, Lee H, Chang Y, Lee H . Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. Aliment Pharmacol Ther. 2018; 47(11):1490-1501. DOI: 10.1111/apt.14623. View

10.

Nakayama Y, Awai K, Funama Y, Hatemura M, Imuta M, Nakaura T . Abdominal CT with low tube voltage: preliminary observations about radiation dose, contrast enhancement, image quality, and noise. Radiology. 2005; 237(3):945-51. DOI: 10.1148/radiol.2373041655. View

11.

Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M . Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019; 49(10):1109-1113. DOI: 10.1111/hepr.13411. View

12.

Kim S, An J, Lim Y, Han S, Lee J, Byun J . MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. JAMA Oncol. 2016; 3(4):456-463. PMC: 5470420. DOI: 10.1001/jamaoncol.2016.3147. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Moyer V . Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160(5):330-8. DOI: 10.7326/M13-2771. View

15.

Lee C, Kim K, Lee J, Park Y, Choi J, Park C . Using low tube voltage (80kVp) quadruple phase liver CT for the detection of hepatocellular carcinoma: two-year experience and comparison with Gd-EOB-DTPA enhanced liver MRI. Eur J Radiol. 2012; 81(4):e605-11. DOI: 10.1016/j.ejrad.2011.12.033. View

16.

Kim H, Kim K, Choi J, Lee J, Lee C, Kang T . Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. BMC Cancer. 2017; 17(1):877. PMC: 5740703. DOI: 10.1186/s12885-017-3819-y. View

17.

Andersson K, Salomon J, Goldie S, Chung R . Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008; 6(12):1418-24. PMC: 4340842. DOI: 10.1016/j.cgh.2008.08.005. View

18.

Hernaez R, Thrift A . High Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation. Clin Gastroenterol Hepatol. 2017; 15(9):1355-1358. DOI: 10.1016/j.cgh.2017.05.002. View

19.

Kim H, An J, Park J, Park S, Lim Y, Lee E . Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis. Hepatology. 2018; 69(4):1599-1613. DOI: 10.1002/hep.30330. View

20.

Mittal S, Kanwal F, Ying J, Chung R, Sada Y, Temple S . Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol. 2016; 65(6):1148-1154. PMC: 5322857. DOI: 10.1016/j.jhep.2016.07.025. View